Filtered By:
Source: American Heart Journal
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 491 results found since Jan 2013.
Cangrelor reduces the risk of ischemic complications in patients with single and multi-vessel disease undergoing PCI: insights from the CHAMPION PHOENIX Trial
Conclusion In the CHAMPION-PHOENIX trial, MVD and SVD patients had similar ischemic outcomes at 48hours and 30days. Cangrelor consistently reduced ischemic complications in both SVD and MVD patients without a significant increase in GUSTO severe bleeding. Clinical Perspectives. What's known? Cangrelor is a novel, intravenous, potent, and rapidly-acting P2Y12 inhibitor, that has been demonstrated to reduce the rate of ischemic events at 48hours in patients who received PCI compared with clopidogrel. What's new? In contrast to prior studies, we found that in this modern cohort, patients with SVD and MVD had a similar risk of...
Source: American Heart Journal - March 9, 2017 Category: Cardiology Source Type: research
Rationale and Design of Family-Based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health (FAMILIA)
Conclusion The FAMILIA studies seek to demonstrate that targeting a younger age group (3–5 years) and utilizing a family-based approach may be a critical strategy in promoting cardiovascular health across the lifespan.
Source: American Heart Journal - February 21, 2017 Category: Cardiology Source Type: research
An Examination of the Relationship between Serum Uric Acid Level, a Clinical History of Gout, and Cardiovascular Outcomes among Patients with Acute Coronary Syndrome
Conclusions In patients with ACS, increasing levels of sUA are associated with an elevated risk of cardiovascular events, regardless of a clinical diagnosis of gout. Further investigation is warranted to determine the mechanism behind this relationship and to delineate whether sUA is an appropriate therapeutic target to reduce cardiovascular risk.
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research
Recurrent MI and stroke post acute coronary syndrome: which is the lesser evil?
Publication date: Available online 21 February 2017 Source:American Heart Journal Author(s): Shahar Lavi, Vladimír Džavík
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research
Use of Prasugrel versus Clopidogrel and Outcomes in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in Contemporary Clinical Practice: Results from the PROMETHEUS Study
Conclusions In contemporary clinical practice, patients receiving prasugrel tend to have a lower-risk profile compared with those receiving clopidogrel. The lower ischemic and bleeding events associated with prasugrel use were no longer evident after accounting for these baseline differences.
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research
Differential Occurrence, Profile, and Impact of First Recurrent Cardiovascular Events After an Acute Coronary Syndrome
Conclusions Approximately 9% of patients experienced a first cardiovascular event in the post-ACS setting during a median follow-up of 1year. While the profile and prognostic implications of stroke versus MI as the first nonfatal event differ substantially, approximately one-third of these patients experienced a second event, typically soon after the first event. These findings have implications for improving post-ACS care and influencing the design of future cardiovascular trials.
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research
A Prospective, Randomized, Open Label Trial of 6Months vs. 12Months Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation In ST-elevation Myocardial Infarction: Rationale and design of the “DAPT-STEMI trial”
Publication date: Available online 20 February 2017 Source:American Heart Journal Author(s): Elvin Kedhi, Enrico Fabris, Martin van der Ent, Mark Kennedy, Pawel Buszman, Clemens von Birgelen, Stéphane Cook, Hans Wedel, Felix Zijlstra Abstract. Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with second-generation drug eluting stents (DES) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the sa...
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research
Atrial fibrillation detected by continuous ECG monitoring using implantable loop recorder to prevent stroke in individuals at risk (The LOOP study): Rationale and design of a large randomized controlled trial
Conclusion The LOOP study will evaluate health benefits and cost-effectiveness of ILR as a screening tool for AF to prevent stroke in patients at risk. Secondary objectives include identification of risk factors for the development of AF and characterization of arrhythmias in the population. The trial holds the potential to influence the future of stroke prevention.
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research
Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting
Conclusion The present study will investigate whether a clinical decision support system integrated in an EHR can increase adherence to guidelines regarding anticoagulant therapy in patients with AF. Trial registration www.clinicaltrials.gov registration number NCT02635685
Source: American Heart Journal - February 15, 2017 Category: Cardiology Source Type: research
Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Conclusions EXSCEL is one of the largest global GLP-1RA trials, evaluating the safety and efficacy of EQW with a broad patient population that may extend generalizability compared to prior GLP-1RA trials (ClinicalTrials.gov number, NCT01144338).
Source: American Heart Journal - February 12, 2017 Category: Cardiology Source Type: research
Association of Measured Platelet Reactivity with Changes in P2Y12 Receptor Inhibitor Therapy and Outcomes Following Myocardial Infarction: Insights into Routine Clinical Practice from the TRANSLATE-ACS Study
Conclusions Only one-third of PCI-treated MI patients with high on-clopidogrel platelet reactivity were switched to a more potent P2Y12 receptor inhibitor. Intensification of antiplatelet therapy was associated with lower risk of ischemic events at 1year among HPR patients.
Source: American Heart Journal - February 10, 2017 Category: Cardiology Source Type: research
Rationale and design of the Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to Cardiovascular Outcomes, Cost Effectiveness and Quality of Life (CONSERVE) trial
Conclusion The CONSERVE trial will determine whether selective catheterization strategy, based on initial CCTA in patients being referred to ICA, is safe and effective.
Source: American Heart Journal - February 3, 2017 Category: Cardiology Source Type: research
Rationale and design of the Medication adherence Improvement Support App For Engagement —Blood Pressure (MedISAFE-BP) trial
Discussion The MedISAFE-BP trial is the first study to rigorously evaluate an mhealth application's effect on blood pressure and medication adherence. The results will inform the potential effectiveness of this simple system in improving cardiovascular disease risk factors and clinical outcomes.
Source: American Heart Journal - February 2, 2017 Category: Cardiology Source Type: research
Transradial access and the risk of periprocedural stroke
Publication date: Available online 28 January 2017 Source:American Heart Journal Author(s): Artur Dziewierz, Zbigniew Siudak, Tomasz Rakowski, Dariusz Dudek
Source: American Heart Journal - January 27, 2017 Category: Cardiology Source Type: research
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes
Conclusions In patients with ACS on dual antiplatelet therapy, spontaneous major bleeding events seem “prognostically equivalent” to spontaneous ischemic complications. This result allows quantitative comparisons between both actual and predicted bleeding and ischemic risks. Our findings help to better define net clinical benefit of antithrombotic treatments and more accurate estimate mortality following ischemic and bleeding events in patients with ACS.
Source: American Heart Journal - January 25, 2017 Category: Cardiology Source Type: research
